Singapore markets closed

Iovance Biotherapeutics, Inc. (IOVA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
12.66+0.82 (+6.93%)
At close: 04:00PM EDT
12.80 +0.14 (+1.11%)
After hours: 07:06PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close11.84
Bid12.64 x 900
Ask12.97 x 3100
Day's range11.90 - 12.74
52-week range6.18 - 27.96
Avg. volume5,162,206
Market cap1.998B
Beta (5Y monthly)0.47
PE ratio (TTM)N/A
EPS (TTM)-2.30
Earnings date02 Nov 2022 - 07 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est27.38
  • Zacks

    Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track

    Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.

  • Zacks

    Iovance (IOVA) Pipeline Aids Growth Amid Lack of Marketed Drugs

    Iovance (IOVA) is progressing well with the clinical development of its pipeline candidates. It expects to file a BLA with the FDA, seeking approval for its lead candidate to treat metastatic melanoma, this August.

  • Motley Fool

    Why Iovance Stock Leaped 17% Higher Today

    As revealed by Securities and Exchange Commission filings dated Thursday, everyone who is anyone at Iovance, it seems, was hitting the buy button. Wayne Rothbaum, a member of the biotech company's board of directors and the president of healthcare sector investment fund Quogue Capital, disclosed two recent purchases of 500,000 shares of Iovance's common stock. Fellow board members Michael Weiser, Ryan Maynard, and Merrill McPeak also loaded up, with recent buys totaling a respective 10,000; 7,500; and 20,000 common shares.